BioN­Tech and Re­gen­eron launch new melanoma col­lab; Har­bour Bio­Med finds in­cu­ba­tion part­ner

BioN­Tech and Re­gen­eron have an­nounced they are col­lab­o­rat­ing on a Phase II tri­al to study how the com­bi­na­tion of the for­mer’s BNT111 can­di­date with the lat­ter’s Lib­tayo can treat melanoma.

The tri­al will en­roll pa­tients with an­ti-PD1-re­frac­to­ry/re­lapsed, un­re­sectable Stage III or IV cu­ta­neous melanoma. More de­tails about the tri­al will be re­vealed at a lat­er date, with the com­pa­nies hop­ing to launch some­time in the fourth quar­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER